Work

Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysis

Year: 2024

Type: article

Study design: Observational Study

Source: Seminars in Arthritis and Rheumatism

DOI: 10.1016/j.semarthrit.2024.152441

Authors: Chio Yokose, Greg Challener, Bohang Jiang, Baijun Zhou, Natalie McCormick, Sruthi Tanikella, Kila Mei Qin Panchot, Minna J. Kohler, Janeth Yinh, Yuqing Zhang, David W. Bates, James L. Januzzi, Meghan Sise, Deborah Wexler, Hyon K. Choi

Institutions: Harvard University, Massachusetts General Hospital, Brigham and Women's Hospital, Baim Institute for Clinical Research

Language: English

Topic: Gout, Hyperuricemia, Uric Acid

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: AstraZeneca, Rheumatology Research Foundation, Takeda Pharmaceuticals U.S.A., Kowa Company, National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases

Awards: Metabolic syndrome, chronic inflammation, and gout: a multi-omics approach, INvestigations In Gout, Hyperuricemia, and comorbidiTies (INSIGHT) Center of Research Translation (CORT), G9000052074, Metabolic syndrome, chronic inflammation, and gout: a multi-omics approach, Research Training in Rheumatology at Massachusetts General Hospital, Personalized Comorbidity-Integrated Gout Care, NOVEL METABOLITE AND MICROBIOTA PATHWAYS FOR HYPERURICEMIA AND GOUT

OpenAlex ID: W4393970951

FWCI: 1.697

Cites: 15

Cited by: 6

Related to: 10